China Pharma Holdings Inc (CPHI)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • AMEX
Market Cap: $22.29M
Last updated: Nov 17, 2026 at 4:25 PM ET
China Pharma Holdings Inc (CPHI) Statistics
China Pharma Holdings (CPHI) has a market cap of $22.29M and an enterprise value of $25.59M. Its share count is up 1156.05% from a year earlier. It kept -114.33% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 14.80% above the market cap, as debt exceeds cash.
| Market Cap | $22.29M |
|---|---|
| Enterprise Value | $25.59M |
| Latest price (Nov 17, 2026) | $0.50 |
Key Dates
The next earnings report is expected on Nov 18, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 18, 2026 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.2x and 0.6x. Its year-end P/S ranged from 0.2x to 80.6x from 2018 to 2025.
| P/S Ratio | 5.2x |
|---|---|
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 66.45% over 52 weeks and trades 26.47% below its 50-day average.
| Beta (1Y) | 2.26 |
|---|---|
| 52-Week Change | -66.45% |
| 1-Month Change | -26.84% |
| 3-Month Change | -53.59% |
| 6-Month Change | -30.14% |
| 5-Year Change | -99.81% |
| 10-Year Change | -99.36% |
| Total Return (1Y) | -66.45% |
| Total Return (3Y CAGR) | -51.81% |
| Total Return (5Y CAGR) | -72.09% |
| Max Drawdown (1Y) | -94.07% |
| Max Drawdown (3Y) | -94.07% |
| Sharpe Ratio (1Y) | -0.37 |
| Correlation with SPY (1Y) | 0.10 |
| 50-Day Average | $0.68 |
| 200-Day Average | $0.79 |
| 52-Week Range | $0.45 to $8.10 |
| RSI (14 Days) | 35.3 |
| Average Volume (20 Days) | 122.14K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.26x current liabilities, and total debt is 0.10x shareholder equity.
| Current Ratio | 0.26x |
|---|---|
| Quick Ratio | 0.08x |
| Debt / Equity | 0.10x |
| Interest Coverage | -44.20x |
Returns and Efficiency
Return on invested capital is -8.69% over the last 12 months, against a 5-year average of -20.23%.
| Return on Equity (ROE) | -12.37% |
|---|---|
| Return on Assets (ROA) | -10.01% |
| Return on Invested Capital (ROIC) | -8.69% |
| Return on Capital Employed (ROCE) | -11.82% |
| ROE (5Y Average) | -53.11% |
| ROA (5Y Average) | -19.63% |
| ROIC (5Y Average) | -20.23% |
| Asset Turnover | 0.13x |
| Inventory Turnover | 2.41x |
| Receivables Turnover | 15.47x |
| Cash Conversion Cycle | -184 days |
Scores
CPHI has an Altman Z-Score of -0.52, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.52 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.91M over the last 12 months is down 10.97% from the 12 months before.
| Revenue | $3.91M |
|---|---|
| Revenue Growth (YoY) | -10.97% |
| Gross Profit | $462.21K |
| Operating Income | -$4.38M |
| Pretax Income | -$4.47M |
| Net Income | -$4.47M |
| EBITDA | -$1.37M |
| EBIT | -$4.38M |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 80.92% of the $44.71M in total assets.
| Cash and Equivalents | $304.87K |
|---|---|
| Total Debt | $3.60M |
| Net Debt | $3.30M |
| Net Debt Per Share | $0.08 |
| Working Capital | -$5.67M |
| Shareholder Equity | $36.18M |
| Book Value Per Share | $0.89 |
| Tangible Book Value | -$2.16M |
| Total Assets | $44.71M |
| Total Liabilities | $8.53M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Operating Cash Flow | -$173.12K |
|---|---|
| FCF Per Share | $0.00 |
| Depreciation and Amortization | $3.01M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -111.84%, against a 5-year average of -58.44%.
| Gross Margin | 11.81% |
|---|---|
| Operating Margin | -111.84% |
| Pretax Margin | -114.33% |
| Net Margin | -114.33% |
| EBITDA Margin | -34.90% |
| EBIT Margin | -111.84% |
| Gross Margin (5Y Average) | -10.17% |
| Operating Margin (5Y Average) | -58.44% |
| Net Margin (5Y Average) | -61.94% |
Growth
Revenue fell 20.03% a year over 3 years.
| Revenue Growth (3Y CAGR) | -20.03% |
|---|---|
| Revenue Growth (5Y CAGR) | -17.53% |
Stock Splits
The last split was a 1-for-10 reverse split on Apr 15, 2025.
| Last Split Date | Apr 15, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 5 similar companies, CPHI has the 2nd highest P/S.
P/S RatioPeer median 1.8x
ROICPeer median -18.01%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.71%
| P/S Ratio | 5.2x vs 1.8x median |
|---|---|
| ROIC | -8.69% vs -18.01% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -10.97% vs +10.71% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CPHI
What is CPHI's market cap?
China Pharma Holdings has a market cap of $22.29M. Its enterprise value, which adds debt and subtracts cash, is $25.59M.
How many shares of CPHI are outstanding?
China Pharma Holdings has 40.52M shares outstanding. The count is up 1156.05% from a year earlier.
Does CPHI pay a dividend?
No. China Pharma Holdings does not pay a dividend.
How much debt does CPHI have?
China Pharma Holdings has $3.60M of total debt and $304.87K of cash and equivalents, a net debt position of $3.30M.
CPHI pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors